Gemini Pharmaceuticals, Inc. – FDA 483, Jun 30, 2015
An FDA inspection of Gemini Pharmaceuticals, Inc. in Commack, NY, revealed significant deficiencies in their drug manufacturing operations. The firm was cited for issues including inadequate validation of packaging equipment, failure to annually inspect reserve drug product samples for deterioration, and incomplete batch production records lacking personnel identification. Additionally, the inspection found problems with laboratory controls, specifically the absence of written analytical procedures for OTC drug products and a lack of traceability for distilled water used in sample preparations.
ID · 355d3e31-f50a-4ffb-8c27-5cb4b6411eb3
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.